• 1
    Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J et al . Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with Type 2 diabetes. Diabetes Care 2007; 30: 16081610.
  • 2
    Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K et al . Liraglutide, a once-daily human GLP-1 analogue improves β-cell function and arginine-stimulated insulin secretion at hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 152156.
  • 3
    Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Ryden L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with Type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004; 1: 4043.
  • 4
    Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B et al . Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209E1215.
  • 5
    Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006; 97: 311.
  • 6
    Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with Type 2 diabetes and microalbuminuria. Diabetologia 2005; 48: 35.